Skip to main content
Erschienen in: Acta Neurologica Belgica 2/2018

10.08.2017 | Original Article

Long-term disability and progression in spinal onset multiple sclerosis

verfasst von: Bedile Irem Tiftikcioglu, Irem Ilgezdi, Yasar Zorlu, Ufuk Sener, Figen Tokucoglu

Erschienen in: Acta Neurologica Belgica | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to investigate the long-term effects of the initial spinal cord (SC) involvement in MS patients. In this retrospective, single-center study, 824 patients with definite MS were screened. A total of 348 patients were excluded for ambiguous documentation of the initial relapse, pediatric onset, diagnosis of primary progressive disease, irregular assessments or visits causing doubt on the onset of progression time, and clinical follow-up duration less than 12 months. Eventually, 476 MS patients were included. Data regarding the demographics, initial symptoms, the degree of recovery from the initial relapse, neuroimaging, cerebrospinal fluid analysis, long-term disability, and progression were collected from the medical registry. The mean duration of follow-up was 7.49 ± 5.30 years. The percentage of patients entering the progressive disease course was 23.3 in the whole group. A total of 157 patients (33.0%) had SC involvement during the first clinical relapse. These patients were significantly older at disease onset (31.69 ± 10.18 vs. 29.55 ± 9.49; p = 0.028), had higher rates of progression (32.5 vs. 18.8%; p = 0.001), and had higher disability scores in long-term follow-up (3.41 ± 2.19 vs. 2.62 ± 1.81; p < 0.001). Mean age at the transition of progressive phase was 41.4 ± 11.2 years. The degree of recovery from the initial relapse significantly affected the long-term disability. The poor recovery from the initial relapse was associated with older onset age and higher EDSS scores. Being older than 40 years during MS onset and poor recovery from the initial relapse exerted an increased risk for progression. The initial SC involvement was related to a more severe relapse with less chance of complete recovery and higher risk for progression. Confirmation of risk factors in different MS cohorts would increase our understanding of the complex disease mechanisms.
Literatur
1.
Zurück zum Zitat Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129(Pt 3):584–594. doi:10.1093/brain/awh721 CrossRefPubMed Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129(Pt 3):584–594. doi:10.​1093/​brain/​awh721 CrossRefPubMed
2.
Zurück zum Zitat Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, Giovannoni G, Miller D, Rashid W, Schmierer K, Shehu A, Silber E, Young C, Zajicek J (2015) Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol 15(4):273–279. doi:10.1136/practneurol-2015-001139 CrossRefPubMed Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, Giovannoni G, Miller D, Rashid W, Schmierer K, Shehu A, Silber E, Young C, Zajicek J (2015) Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol 15(4):273–279. doi:10.​1136/​practneurol-2015-001139 CrossRefPubMed
3.
Zurück zum Zitat Amato MP, Ponziani G (2000) A prospective study on the prognosis of multiple sclerosis. Neurol Sci 21(4 Suppl 2):S831–S838CrossRefPubMed Amato MP, Ponziani G (2000) A prospective study on the prognosis of multiple sclerosis. Neurol Sci 21(4 Suppl 2):S831–S838CrossRefPubMed
4.
Zurück zum Zitat Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126(Pt 4):770–782CrossRefPubMed Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126(Pt 4):770–782CrossRefPubMed
7.
Zurück zum Zitat McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127CrossRefPubMed McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127CrossRefPubMed
8.
Zurück zum Zitat Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846. doi:10.1002/ana.20703 CrossRefPubMed Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846. doi:10.​1002/​ana.​20703 CrossRefPubMed
9.
Zurück zum Zitat Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.1002/ana.22366 CrossRefPubMedPubMedCentral Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.​1002/​ana.​22366 CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH (2013) Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 19(2):188–198. doi:10.1177/1352458512451510 CrossRefPubMed Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH (2013) Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 19(2):188–198. doi:10.​1177/​1352458512451510​ CrossRefPubMed
12.
Zurück zum Zitat Novotna M, Paz Soldan MM, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M, Kantarci OH (2015) Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology 85(8):722–729. doi:10.1212/WNL.0000000000001856 CrossRefPubMedPubMedCentral Novotna M, Paz Soldan MM, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M, Kantarci OH (2015) Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology 85(8):722–729. doi:10.​1212/​WNL.​0000000000001856​ CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F (2013) Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 80(1):69–75. doi:10.1212/WNL.0b013e31827b1a67 CrossRefPubMed Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F (2013) Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 80(1):69–75. doi:10.​1212/​WNL.​0b013e31827b1a67​ CrossRefPubMed
15.
Zurück zum Zitat Binquet C, Quantin C, Le Teuff G, Pagliano JF, Abrahamowicz M, Moreau T (2006) The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis. Neuroepidemiology 27(1):45–54. doi:10.1159/000094380 CrossRefPubMed Binquet C, Quantin C, Le Teuff G, Pagliano JF, Abrahamowicz M, Moreau T (2006) The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis. Neuroepidemiology 27(1):45–54. doi:10.​1159/​000094380 CrossRefPubMed
16.
Zurück zum Zitat Borreani C, Bianchi E, Pietrolongo E, Rossi I, Cilia S, Giuntoli M, Giordano A, Confalonieri P, Lugaresi A, Patti F, Grasso MG, de Carvalho LL, Palmisano L, Zaratin P, Battaglia MA, Solari A, Np Pe (2014) Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. PLoS One 9(10):e109679. doi:10.1371/journal.pone.0109679 CrossRefPubMedPubMedCentral Borreani C, Bianchi E, Pietrolongo E, Rossi I, Cilia S, Giuntoli M, Giordano A, Confalonieri P, Lugaresi A, Patti F, Grasso MG, de Carvalho LL, Palmisano L, Zaratin P, Battaglia MA, Solari A, Np Pe (2014) Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. PLoS One 9(10):e109679. doi:10.​1371/​journal.​pone.​0109679 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Kulu U, Tiftikcioglu BI, Zorlu Y, Cetiner M, Sener U, Tuna G, Kirkali G (2017) Efficacy of different durations of intravenous methylprednisolone treatment in relapses of multiple sclerosis. Noro Psikiyatr Ars 54(1):57–61. doi:10.5152/npa.2016.12382 CrossRefPubMed Kulu U, Tiftikcioglu BI, Zorlu Y, Cetiner M, Sener U, Tuna G, Kirkali G (2017) Efficacy of different durations of intravenous methylprednisolone treatment in relapses of multiple sclerosis. Noro Psikiyatr Ars 54(1):57–61. doi:10.​5152/​npa.​2016.​12382 CrossRefPubMed
Metadaten
Titel
Long-term disability and progression in spinal onset multiple sclerosis
verfasst von
Bedile Irem Tiftikcioglu
Irem Ilgezdi
Yasar Zorlu
Ufuk Sener
Figen Tokucoglu
Publikationsdatum
10.08.2017
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 2/2018
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-017-0828-1

Weitere Artikel der Ausgabe 2/2018

Acta Neurologica Belgica 2/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.